Novel Angiogenic Domains: Use in Identifying Unique Transforming and Tumor Promoting Pathways in Human Breast Cancer
Abstract
Our research program focus on novel observations to seek oncogenes in human breast cancer that will cooperate with stable expression of the angiogenic domains of pleiotrophin(PTN) and midkine(MK) to establish an "angiogenic switch" and, to identify downstream genes in the angiogenic pathway itself that are activated by the PTN and Mk angiogenic domains. In the past year, we have developed MCFlOA-PTN, -PTN mutant cell lines. Also, we have obtained an appropriate cDNA library from primary human breast cancers as a source of genes potentially able to use PTN to effectively enhance MCF10A cell growth in the nude mouse. The library is not derived from a cell line, but rather is derived from primary tissues, thereby avoiding the problems of mutations introduced in cell lines through prolonged passage. Furthermore, we have identify three downstream interactive proteins with the receptor protein RPTP-beta/zeta and thus of the PTN signaling pathway in human breast cancer cells. We are pleased with progress thus tar. We have established the base for obtaining results we sought in submitting the proposal. We have advanced understanding of pleiotrophin and midkine in the promotion of human breast cancer cells. We have identified and initiated understanding of the functions of pleiotrophin in these cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2001
- Accession Number
- ADA398142
Entities
People
- Thomas F. Deuel
Organizations
- Beth Israel Deaconess Medical Center